These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34864194)

  • 1. A survey of the clinical pipeline in neuroscience.
    Brown DG; Wobst HJ
    Bioorg Med Chem Lett; 2022 Jan; 56():128482. PubMed ID: 34864194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miRNAs: Key Players in Neurodegenerative Disorders and Epilepsy.
    Karnati HK; Panigrahi MK; Gutti RK; Greig NH; Tamargo IA
    J Alzheimers Dis; 2015; 48(3):563-80. PubMed ID: 26402105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heat shock proteins: therapeutic drug targets for chronic neurodegeneration?
    Sajjad MU; Samson B; Wyttenbach A
    Curr Pharm Biotechnol; 2010 Feb; 11(2):198-215. PubMed ID: 20166961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Australian neuroscience in 2006--highlights from the scientific meeting.
    Doggrell SA
    Drug News Perspect; 2006 Jun; 19(5):300-6. PubMed ID: 16941052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain penetrant kinase inhibitors: Learning from kinase neuroscience discovery.
    Shi Y; Mader M
    Bioorg Med Chem Lett; 2018 Jun; 28(11):1981-1991. PubMed ID: 29752185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanding therapeutic opportunities for neurodegenerative diseases: A perspective on the important role of phenotypic screening.
    Swalley SE
    Bioorg Med Chem; 2020 Feb; 28(3):115239. PubMed ID: 31889605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of rosmarinic acid on nervous system disorders: an updated review.
    Ghasemzadeh Rahbardar M; Hosseinzadeh H
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Oct; 393(10):1779-1795. PubMed ID: 32725282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodifying and neuroprotective effects of noscapine: Implications for multiple sclerosis, neurodegenerative, and psychiatric disorders.
    Altinoz MA; Guloksuz S; Ozpinar A
    Chem Biol Interact; 2022 Jan; 352():109794. PubMed ID: 34963564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omega-3 fatty acid eicosapentaenoic acid. A new treatment for psychiatric and neurodegenerative diseases: a review of clinical investigations.
    Song C; Zhao S
    Expert Opin Investig Drugs; 2007 Oct; 16(10):1627-38. PubMed ID: 17922626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological Alternatives for the Treatment of Neurodegenerative Disorders: Wasp and Bee Venoms and Their Components as New Neuroactive Tools.
    Silva J; Monge-Fuentes V; Gomes F; Lopes K; dos Anjos L; Campos G; Arenas C; Biolchi A; Gonçalves J; Galante P; Campos L; Mortari M
    Toxins (Basel); 2015 Aug; 7(8):3179-209. PubMed ID: 26295258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antiapoptotic activity of melatonin in neurodegenerative diseases.
    Wang X
    CNS Neurosci Ther; 2009; 15(4):345-57. PubMed ID: 19818070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders.
    Forlenza OV; De-Paula VJ; Diniz BS
    ACS Chem Neurosci; 2014 Jun; 5(6):443-50. PubMed ID: 24766396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and experimental neuroprotection in neurodegenerative diseases is a therapeutic option for the future of amyotrophic lateral sclerosis (ALS). Preface.
    Ludolph AC; Drory VE
    J Neurol; 2000 Dec; 247 Suppl 6():VI/1. PubMed ID: 19714407
    [No Abstract]   [Full Text] [Related]  

  • 15. Mechanistic new insights of flavonols on neurodegenerative diseases.
    Tahir MS; Almezgagi M; Zhang Y; Bashir A; Abdullah HM; Gamah M; Wang X; Zhu Q; Shen X; Ma Q; Ali M; Solangi ZA; Malik WS; Zhang W
    Biomed Pharmacother; 2021 May; 137():111253. PubMed ID: 33545661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases.
    Dhib-Jalbut S; Arnold DL; Cleveland DW; Fisher M; Friedlander RM; Mouradian MM; Przedborski S; Trapp BD; Wyss-Coray T; Yong VW
    J Neuroimmunol; 2006 Jul; 176(1-2):198-215. PubMed ID: 16983747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P2X7 receptor: an emerging target in central nervous system diseases.
    Sperlágh B; Illes P
    Trends Pharmacol Sci; 2014 Oct; 35(10):537-47. PubMed ID: 25223574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective effects of chrysin: From chemistry to medicine.
    Nabavi SF; Braidy N; Habtemariam S; Orhan IE; Daglia M; Manayi A; Gortzi O; Nabavi SM
    Neurochem Int; 2015 Nov; 90():224-31. PubMed ID: 26386393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.
    Dunkel P; Chai CL; Sperlágh B; Huleatt PB; Mátyus P
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1267-308. PubMed ID: 22741814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P7C3 and an unbiased approach to drug discovery for neurodegenerative diseases.
    Pieper AA; McKnight SL; Ready JM
    Chem Soc Rev; 2014 Oct; 43(19):6716-26. PubMed ID: 24514864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.